• Anti-Diabetic Drugs and Fracture Risk: Network Evidence

  2026-10-03

  A 2021 systematic review and network meta-analysis synthesized 117 randomized controlled trials involving 221,364 participants to compare fracture outcomes across anti-diabetic therapies. The analysis identified statistically different findings for trelagliptin, albiglutide, and voglibose, while most other agents—including ertugliflozin—did not show statistically significant differences versus comparators, underscoring the limits of ranking drugs from sparse fracture events.

• EPZ-6438: From EZH2 Mechanism to Translation

  2026-10-01

  EPZ-6438 is a selective EZH2 inhibitor that connects PRC2 pathway biology with practical translational strategies across EZH2-mutant lymphoma, malignant rhabdoid tumor, and HPV-associated cervical cancer models. This thought-leadership guide interprets the evidence, outlines rigorous validation workflows, and identifies the boundaries between promising mechanism and clinical readiness.

• FCCP as a Metabolic Probe in HIF Research

  2026-10-01

  FCCP, or carbonyl cyanide p-trifluoromethoxyphenylhydrazone, can do more than collapse the mitochondrial proton gradient. This article presents an assay-centered framework for connecting respiratory perturbation with HIF signaling, AMPK-driven macrophage metabolism, and better experimental decisions.

• AI-10-49: Mapping RUNX1 Reactivation in AML

  2026-09-30

  AI-10-49 is a selective CBFβ-SMMHC inhibitor for dissecting fusion-driven transcriptional dysfunction in inv(16) acute myeloid leukemia. This guide presents a temporal, multi-assay strategy that separates target engagement, RUNX1 chromatin recovery, downstream survival signaling, and leukemia phenotypes.

• Trelagliptin Succinate: AMPK–SOX9 Assay Logic

  2026-09-30

  Trelagliptin succinate research extends beyond glucose control into a mechanistically resolved chondrocyte model. This guide connects DPP-4 enzyme inhibition with AMPK–SOX-9 biology and practical decisions for diabetes mellitus research and inflammatory cartilage assays.

• Etoposide (VP-16): From DNA Breaks to Senescence

  2026-09-29

  Etoposide (VP-16) is more than a cytotoxic benchmark: it is a mechanistic probe for linking topoisomerase II-mediated DNA damage with apoptosis, persistent arrest, and senescence-associated biomarkers. This translational framework shows how to combine DNA damage assays with cell-surface LAMP1 profiling to produce more informative cancer and senescence research models.

• RUNX2, IFN-I, and ICB Resistance in Osteosarcoma

  2026-09-29

  This study identifies a RUNX2–NCOR1–HDAC3 repressor complex that epigenetically suppresses type I interferon signaling in osteosarcoma. The findings support combining HDAC3 inhibition with anti-PD-1 therapy to restore interferon activity while addressing the compensatory increase in PD-L1 and PD-L2.

• Canagliflozin: Reading Negative mTOR Screens

  2026-09-28

  Canagliflozin hemihydrate is best understood not only as an SGLT2 tool, but also as an informative boundary compound in mTOR screening. This article connects renal glucose reabsorption biology with drug-sensitized yeast assay design and shows how to interpret a negative TOR result.

• Meropenem in Resistance Research Workflows

  2026-09-28

  Use Meropenem as a defined β-lactam comparator in susceptibility testing and Gram-negative infection models—not as a shortcut for predicting activity against resistant isolates. This guide connects careful assay design with recent Enterobacter cloacae resistance surveillance and practical troubleshooting.

• Neomycin sulfate for RNA, DNA, and Channel Studies

  2026-09-27

  Neomycin sulfate is a mechanistic probe for nucleic-acid structure and ryanodine receptor channel experiments—not simply an antimicrobial. This workflow-focused guide shows how to build controlled pilot assays and interpret them alongside allergic-rhinitis microbiome research without implying the compound was tested in that study.

• EGFR/HER2 Inhibition in Translational Oncology

  2026-09-26

  A translational perspective on using BMS 599626 dihydrochloride to interrogate EGFR/HER2 signaling, connect pathway measurements to tumor phenotypes, and distinguish established evidence from emerging senescence questions.

• ATG4B Links Energy Deficiency to AML DNA Repair

  2026-09-25

  The study identifies a route by which energy deficiency can compromise genome maintenance: ATG4B moves into the nucleus, binds PRMT1, and reduces PRMT1-dependent MRE11 methylation. In AML models, ATG4B inhibition strengthened DNA damage responses and was associated with lower mutation burden and longer survival, making the pathway a mechanistic lead rather than an established treatment strategy.

• eIF4F, AKT1 and EZH2 Blockade in Resistant Melanoma

  2026-09-25

  In BRAFV600E A375 melanoma models, eIF4F inhibition with RocA triggered time-dependent ERK1/2–EZH2 and AKT1–eIF4E responses associated with reduced treatment sensitivity. The study reports that combining eIF4F, AKT1, and EZH2 inhibition improved anticancer effects in vitro and in vivo, offering a mechanistic rationale for testing multi-pathway strategies while leaving questions about dose, model breadth, and clinical translation open.

• Etoposide (VP-16): DNA Damage Research Guide

  2026-09-24

  Etoposide (VP-16) is a DNA topoisomerase II inhibitor used to study DNA damage and apoptosis in cancer models. Product-listed potency varies substantially by assay and cell line, so reported IC50 values should be treated as model-specific benchmarks rather than universal dose recommendations.

• miR-18a–ALOXE3 Signaling in Glioblastoma

  2026-09-24

  The study links elevated miR-18a with suppression of ALOXE3, connecting altered lipid metabolism to reduced ferroptotic sensitivity and increased glioblastoma cell migration. Its findings position the miR-18a/ALOXE3 axis as a mechanistic research target, while highlighting that ferroptosis and apoptosis are distinct outcomes that require separate experimental interpretation.

8645 records 1/577 page Next 12345 下5页 Last page